{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:53:35Z","timestamp":1791312815999,"version":"4.3.1"},"reference-count":23,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2010,5,26]],"date-time":"2010-05-26T00:00:00Z","timestamp":1274832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2010,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>In a phase 3 study, the authors assessed the effects of dasatinib at doses of 140 mg once daily and 70 mg twice daily in patients who had either chronic myeloid leukemia (CML) in advanced phases or Philadelphia chromosome\u2010positive acute lymphoblastic leukemia and were resistant or intolerant to imatinib. In the current report, the results for patients with CML in blast phase after 2 years of follow\u2010up are reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Patients were stratified according to whether they had CML in myeloid blast phase (MBP\u2010CML) or in lymphoid blast phase (LBP\u2010CML) and were randomized (1:1) within each stratum to receive either oral dasatinib 140 mg once daily or 70 mg twice daily.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>In patients with MBP\u2010CML, the major hematologic response rate was 28% for both regimens; and, in patients with LBP\u2010CML, the major hematologic response rate was 42% for once\u2010daily dasatinib and 32% for twice\u2010daily dasatinib. The major cytogenetic response rates were 25% for once\u2010daily dasatinib and 28% for twice\u2010daily dasatinib in patients with MBP\u2010CML, and the respective rates in patients with LBP\u2010CML were 50% and 40%. The overall survival rate at 24 months was 24% for once\u2010daily dasatinib and 28% for twice\u2010daily dasatinib in patients with MBP\u2010CML, and the respective values in patients with LBP\u2010CML were 21% and 16%. Adverse events indicated a trend toward improved tolerability for the once\u2010daily regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>The current results suggested that dasatinib 140 mg once daily had similar efficacy and improved tolerability relative to the 70\u2010mg twice\u2010daily regimen in patients with imatinib\u2010resistant, blast phase CML. Cancer 2010. \u00a9 2010 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.25123","type":"journal-article","created":{"date-parts":[[2010,5,27]],"date-time":"2010-05-27T02:41:26Z","timestamp":1274928086000},"page":"3852-3861","source":"Crossref","is-referenced-by-count":106,"title":["Dasatinib in imatinib\u2010resistant or imatinib\u2010intolerant chronic myeloid leukemia in blast phase after 2 years of follow\u2010up in a phase 3 study"],"prefix":"10.1002","volume":"116","author":[{"given":"Giuseppe","family":"Saglio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeow Tee","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"Masszi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Maloisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Erben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Paquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Brigid","family":"Bradley\u2010Garelik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Dombret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,4]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2004.03.005"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4111"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3547"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3530"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13068"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402741"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn188"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm049486a"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046839"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.221"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046888"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-073528"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-186817"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2926.2926","article-title":"Dasatinib 140 MG ONCE Daily (QD) has equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with imatinib\u2010resistant or \u2010intolerant Philadelphia chromosome\u2010positive acute lymphoblastic leukemia (Ph+ ALL): 2\u2010year data from CA180\u2010035 [abstract]","volume":"112","author":"Larson RA","year":"2008","journal-title":"Blood."},{"key":"e_1_2_6_20_2","first-page":"175s","article-title":"Dasatinib pharmacokinetics and exposure\u2010response (E\u2010R): relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML) [abstract]","volume":"26","author":"Wang X","year":"2008","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.11.001"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-113969"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22778"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1182\/blood.V108.11.4520.4520","article-title":"The role of dasatinib in patients with Philadelphia (Ph) positive acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML) relapsing after stem cell transplantation (SCT) [abstract]","volume":"108","author":"Atallah E","year":"2006","journal-title":"Blood"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.25123","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.25123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T09:43:48Z","timestamp":1760262228000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.25123"}},"subtitle":["Efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily"],"short-title":[],"issued":{"date-parts":[[2010,8,4]]},"references-count":23,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2010,8,15]]}},"alternative-id":["10.1002\/cncr.25123"],"URL":"https:\/\/doi.org\/10.1002\/cncr.25123","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,4]]}}}